Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
85064 trials found · Page 43 of 4254
-
Could this shot stop your first heart attack?
Prevention Recruiting nowThe primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for a first major cardiovascular event with elevated li…
Phase: PHASE3 • Sponsor: Amgen • Aim: Prevention
Last updated Apr 06, 2026 14:18 UTC
-
New drug trial aims to stop lung Cancer's return after surgery
Disease control Recruiting nowThe purpose of this phase 3 multicenter double-blind randomized study is to assess the use of taletrectinib in the early-stage non-small cell lung cancer (NSCLC). The study compares taletrectinib (study drug) versus placebo (sugar pill) in patients with ROS1-fusion positive stage…
Phase: PHASE3 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Apr 22, 2026 16:00 UTC
-
High-Power radiation trial aims to extend lives in tough pancreatic cancer
Disease control Recruiting nowThis phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial 4-6 months of chemotherapy. Usual care options include additional chemotherapy, …
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Apr 22, 2026 15:58 UTC
-
Breakthrough trial tests promising new combo against aggressive breast cancer
Disease control Recruiting nowThis study is to evaluate the progression-free survival (PFS) of SHR-A1811 combined with SHR-1316 in the first-line treatment of PD-L1-positive locally recurrent unresectable or metastatic triple-negative breast cancer with Toripalimab combined with Nab-paclitaxel, as assessed by…
Phase: PHASE3 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Apr 06, 2026 14:05 UTC
-
New transplant prep aims to stop blood Cancer's return
Disease control Recruiting nowThis is a prospective, multicenter, randomized controlled trial designed to evaluate the efficacy and safety of venetoclax-enhanced BUCY (Ven-BUCY) conditioning compared to the standard BUCY regimen in patients with high-risk acute myeloid leukemia (AML) or myelodysplastic syndro…
Phase: NA • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Apr 23, 2026 12:44 UTC
-
Scientists test cancer drug's potential to free HIV patients from daily pills
Disease control ENROLLING_BY_INVITATIONEven though HIV medicine stops the virus from making more copies of itself, the virus remains in the body by hiding inside of immune cells. This hidden virus is referred to as the "latent reservoir." Researchers on this team are studying whether stimulating the immune system can …
Phase: PHASE2 • Sponsor: Michael Peluso, MD • Aim: Disease control
Last updated Apr 14, 2026 13:09 UTC
-
Breakthrough trial aims to extend lives in aggressive lung cancer
Disease control Recruiting nowThe main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Apr 21, 2026 12:43 UTC
-
New cell therapy targets stubborn leukemia after failed transplant
Disease control Recruiting nowTo observe the efficacy and safety of CD7-targeted chimeric antigen receptor T cells in the treatment of T-lymphoblastic leukaemia/lymphoma with postive measurable residual disease positive post allogeneic stem cell transplantation
Phase: PHASE1 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
New cell therapy trial targets devastating amyloid disease
Disease control Recruiting nowOpen-label Phase 1b/2 study with primary objective of this study is to evaluate the safety, tolerability and efficacy of AZD0120 in participants with light chain (AL) amyloidosis.
Phase: PHASE1, PHASE2 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Apr 14, 2026 13:08 UTC
-
New drug combo aims to boost stomach cancer surgery success
Disease control Recruiting nowThis study investigates treatment of cadonilimab or placebo combined with SOX chemotherapy (oxaliplatin + tegafur-gimeracil-oteracil potassium) given before surgery (neoadjuvant) and cadonilimab or placebo combined with SOX chemotherapy after surgery (adjuvant), will work and be …
Phase: PHASE3 • Sponsor: Akeso • Aim: Disease control
Last updated Apr 22, 2026 15:59 UTC
-
New program aims to build 'Villages of Care' to save teens from suicide
Prevention Recruiting nowThe goal of this pilot randomized control trial (RCT) is to test the feasibility of Caring Connections, a Culturally Adapted Linking Individuals Needing Care (CA-LINC) suicide prevention care coordination intervention for high-risk suicidal youth. This consumer-, community-, and …
Phase: NA • Sponsor: University of North Carolina, Chapel Hill • Aim: Prevention
Last updated Mar 16, 2026 15:27 UTC
-
Breakthrough trial offers hope for stroke patients on blood thinners
Disease control Recruiting nowAn investigator-initiated, multicenter, randomized, placebo-controlled, double-blind trial to determine the efficacy and safety of intravenous tenecteplase thrombolysis in acute ischemic stroke (AIS) patients with recent direct oral anticoagulants (DOACs) intake in improving the …
Phase: PHASE3 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Apr 21, 2026 12:44 UTC
-
Breakthrough drug trial offers hope for kids with devastating genetic epilepsy
Disease control Recruiting nowA Randomized, Multi-Center, Double-Blind, Sham-Procedure-Controlled Clinical Trial to Investigate the Efficacy and Safety of Elsunersen in Pediatric Participants with Early Onset SCN2A Developmental and Epileptic Encephalopathy
Phase: PHASE3 • Sponsor: Praxis Precision Medicines • Aim: Disease control
Last updated Apr 23, 2026 12:43 UTC
-
Double-Donor transplant trial aims to boost blood cancer survival
Disease control Recruiting nowThe purpose of this study is to see if see if adding the specific combination of donors can result in acceptable levels of survival without evidence of disease.
Phase: PHASE2 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Apr 22, 2026 15:59 UTC
-
New Two-Pronged attack on advanced cancers enters human trials
Disease control Recruiting nowThis study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in participants with histologically or cytologically confirmed solid tumors that are advanc…
Phase: PHASE1, PHASE2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Apr 09, 2026 19:33 UTC
-
New drug trial aims to slash sickle cell pain crises
Disease control Recruiting nowThis is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, group-sequential study (Part A), followed by an open-label LTE period (Part B) to investigate the efficacy, and safety of rilzabrutinib in participants with sickle-cell disease (SCD). Study deta…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New hope for Tough-to-Treat blood cancer: experimental drug added to standard chemo
Disease control Recruiting nowA Randomised, Double-blind, Multicenter Phase Ⅲ Study to Evaluate the Efficacy and Safety of Tucidinostat versus Placebo in Combination with CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma with Follicular Helper of T Cell Phenotype
Phase: PHASE3 • Sponsor: Chipscreen Biosciences, Ltd. • Aim: Disease control
Last updated Apr 20, 2026 16:18 UTC
-
New injection aims to control hepatitis b virus after stopping daily pills
Disease control OngoingThis study is a randomized, double-blind, multicenter phase 3 clinical trial to evaluate the efficacy and safety of AHB-137 injection in participants with HBeAg-negative CHB treated with NAs.
Phase: PHASE3 • Sponsor: Ausper Biopharma Co., Ltd. • Aim: Disease control
Last updated Apr 17, 2026 16:11 UTC
-
New targeted cancer drug challenges standard treatment in major lung cancer trial
Disease control Recruiting now"In this study researchers are testing GSK5764227, a new medicine that targets specific proteins (B7-H3) on cancer cells, thereby reducing the cancers ability to grow and spread. This study specifically aims to evaluate how well GSK5764227 works in treating relapsed SCLC compared…
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New drug duo targets aggressive blood cancer after other treatments fail
Disease control Recruiting nowA single-arm, open-label, multi-center clinical study of glofitamab combined with lenalidomide in high risk patients with relapsed or refractory Mantle Cell Lymphoma previously treated with a BTK Inhibitor. Patients will be eligible if they have received one or more prior lines …
Phase: PHASE2 • Sponsor: Peking University Third Hospital • Aim: Disease control
Last updated Apr 15, 2026 16:16 UTC